Shadman, M., Burke, J. M., Cultrera, J., Yimer, H. A., Zafar, S. F., Misleh, J., . . . Sharman, J. P. Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: Updated results. Elsevier.
Chicago Style (17th ed.) CitationShadman, Mazyar, et al. Zanubrutinib Is Well Tolerated and Effective in Patients with CLL/SLL Intolerant of Ibrutinib/acalabrutinib: Updated Results. Elsevier.
MLA (9th ed.) CitationShadman, Mazyar, et al. Zanubrutinib Is Well Tolerated and Effective in Patients with CLL/SLL Intolerant of Ibrutinib/acalabrutinib: Updated Results. Elsevier.
Warning: These citations may not always be 100% accurate.